Curated News
By: NewsRamp Editorial Staff
May 28, 2026
Jupiter Neurosciences Raises $2M in Direct Offering for CNS Pipeline
TLDR
- Jupiter Neurosciences raised $2 million, strengthening its cash position for advancing JOTROL in Parkinson's disease trials.
- The company sold 7,142,858 shares via a registered direct offering, with D. Boral Capital as placement agent, under an effective SEC shelf registration.
- Jupiter's funding supports development of treatments for CNS disorders like Parkinson's, aiming to improve patients' quality of life.
- Jupiter's pipeline includes JOTROL, a resveratrol formulation, and a psychedelic NCE, targeting neuroinflammation in novel ways.
Impact - Why it Matters
This news matters because it signals continued investor confidence in Jupiter Neurosciences' approach to tackling central nervous system disorders and neuroinflammation, areas with high unmet medical need. The $2 million raise will fund critical clinical trials, including the Phase IIa study of JOTROL for Parkinson's disease, and support the integration of ALA-002, a psychedelic NCE, into the pipeline. For investors, it highlights the company's strategic moves in a growing CNS therapeutics market. For patients and the broader healthcare community, it represents potential advancements in treatments for debilitating conditions like Parkinson's disease and other neuroinflammatory disorders.
Summary
Jupiter Neurosciences (NASDAQ: JUNS), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, has announced the closing of a securities purchase agreement for the sale of 7,142,858 shares of common stock in a registered direct offering, generating gross proceeds of approximately $2.0 million. The offering was led by D. Boral Capital LLC as the exclusive placement agent and was conducted under the company’s effective shelf registration statement on Form S-3, declared effective by the U.S. Securities and Exchange Commission on April 24, 2026. This capital raise comes at a pivotal time as Jupiter Neurosciences advances its therapeutic pipeline targeting central nervous system (CNS) disorders and neuroinflammation.
Jupiter Neurosciences is developing a robust pipeline, including its lead program JOTROL™, a proprietary enhanced bioavailability resveratrol formulation currently in a Phase IIa clinical trial for Parkinson’s disease. The company also commercializes Nugevia™, a consumer longevity supplement, and recently acquired the U.S. rights to ALA-002, a next-generation, patented psychedelic NCE, strengthening its CNS pipeline amid evolving U.S. regulatory policies. This combination of innovative therapeutics and consumer products positions Jupiter Neurosciences to address significant unmet medical needs in neurology and longevity. The funds from the offering are expected to support ongoing clinical trials and pipeline development.
MissionIR (“MIR”), a specialized communications platform within the Dynamic Brand Portfolio @ IBN, disseminated this news. MIR assists IR firms with syndicated content to enhance visibility for private and public companies. The platform offers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. With a seasoned team of contributing journalists and writers, MIR is uniquely positioned to serve companies aiming to reach investors, influencers, and the public.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Jupiter Neurosciences Raises $2M in Direct Offering for CNS Pipeline
